DreamCIS (223250.KQ) Stock Price

DreamCIS Price

CLOSED
3,865.00
​
Market closed

Revenue has compounded at 19.6% per year over the past 8 years to 66.63 B KRW. Earnings per share have declined at 13.8% per year over the last 7 years. DreamCIS's net margin stands at 10.7%, down from 12.3% several years earlier.

DreamCIS stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DreamCIS business model & stock analysis

DreamCIS Inc. is a company based in Seoul, South Korea, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company went public on May 22, 2020, with its stock listed under the ticker 223250.KQ and ISIN KR7223250002. DreamCIS Inc. provides clinical online information and consultation services, focusing on regulatory post-marketing surveillance (rPMS), clinical trials, and non-interventional studies (NIS). The company serves both domestic and international markets, offering its services to clients seeking support in clinical research and regulatory compliance. Its headquarters are located in Seoul, South Korea. The company's website is http://www.dreamcis.com/, which serves as a primary source for further information about its services and operations. DreamCIS Inc. does not provide detailed information about its founding year, specific leadership, or financial figures beyond its IPO date, and no acquisitions or additional product names are mentioned in the provided data. The company's services are primarily aimed at facilitating clinical research and ensuring adherence to regulatory standards in the life sciences sector.

Frequently asked questions about DreamCIS

Converted at the current exchange rate, the DreamCIS share trades at 2.56 EUR (3,865.00 KRW).

The expected revenue of DreamCIS is 90.00 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of DreamCIS is 10.43 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of DreamCIS is currently 8.82. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the DreamCIS stock.

The price-to-sales ratio (P/S) of DreamCIS is currently 1.02. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the DreamCIS stock.

The Eulerpool Quality Score for DreamCIS is 2/10.

The ISIN of DreamCIS is KR7223250002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of DreamCIS is 223250.KQ. The ticker symbol is used to trade DreamCIS shares on the stock exchange.

Fair ValueTerminal
3,169.30 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website dreamcis.com
Country
South Korea
Currency
KRW
Initial public offering
May 22, 2020
ISIN
KR7223250002
Cusip
Y2R0F2109
Market capitalization
91.86 B KRWLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
8.80
P/Ee 2027
7.40
P/S
P/Se
1.02
EV/EBIT
17.54
P/B Ratio
1.20
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
9.33 %
Last updated Oct 16, 2026, 4:29 PM

DreamCIS Peer Group

DreamCIS FIGI

223250:KS · BBG002PC1768223250:KQ · BBG00T5HSTC6

All fundamentals and in-depth analysis of DreamCIS

Our stock analysis for DreamCIS stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DreamCIS. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.